Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JONATHAN B KING

Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family

NPI
1174023352
CMS profile
10822739
Location
TYLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$11,836.09

113 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 3; records 51–100 of 113 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JONATHAN B KING

NPI 1174023352 · CMS profile ID 10822739

Physician Assistants & Advanced Practice Nursing Providers / Nurse Practitioner / Family

TYLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 113 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1174023352?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JONATHAN B KING, NPI 1174023352, CMS profile ID 10822739. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 113 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174023352?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JONATHAN B KING, NPI 1174023352, CMS profile ID 10822739. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 113 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174023352?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JONATHAN B KING, NPI 1174023352, CMS profile ID 10822739, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 113 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1174023352?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

113 matching records · $11,836.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 113 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 113.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $16.1208/08/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114326549 CMS
Novartis Pharmaceuticals Corporation $15.2908/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086997092 CMS
ABBVIE INC. $12.2507/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1107465891 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.0207/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144978268 CMS
Myriad Genetic Laboratories, Inc. $28.5107/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152547920 CMS
JAZZ PHARMACEUTICALS INC. $23.6107/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151297394 CMS
Novartis Pharmaceuticals Corporation $83.3307/15/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086997120 CMS
AstraZeneca Pharmaceuticals LP $26.1607/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105506648 CMS
ADC Therapeutics America, Inc. $17.7407/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121190699 CMS
AstraZeneca Pharmaceuticals LP $21.9107/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105548445 CMS
Apellis Pharmaceuticals, Inc. $27.9607/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154032043 CMS
Merck Sharp & Dohme LLC $14.3806/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141749495 CMS
Regeneron Healthcare Solutions, Inc. $11.7306/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114326543 CMS
Regeneron Healthcare Solutions, Inc. $4.5406/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114326545 CMS
PFIZER INC. $12.2106/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131491116 CMS
PFIZER INC. $14.2606/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132050688 CMS
ABBVIE INC. $17.4606/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1107465889 CMS
Incyte Corporation $23.6106/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141235719 CMS
ABBVIE INC. $900.0006/18/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1107465887 CMS
E.R. Squibb & Sons, L.L.C. $19.7906/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101808927 CMS
Novartis Pharmaceuticals Corporation $83.3306/13/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086997118 CMS
Regeneron Healthcare Solutions, Inc. $6.7905/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114326541 CMS
Aveo Pharmaceuticals, Inc. $27.5205/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143494247 CMS
Regeneron Healthcare Solutions, Inc. $17.3905/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114326539 CMS
ABBVIE INC. $28.3105/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1107465885 CMS
Bayer Healthcare Pharmaceuticals Inc. $20.9205/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086368179 CMS
Novartis Pharmaceuticals Corporation $5.0905/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086997078 CMS
GlaxoSmithKline, LLC. $18.3905/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116555771 CMS
Myriad Genetic Laboratories, Inc. $33.7105/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152547918 CMS
Novartis Pharmaceuticals Corporation $83.3305/16/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086997116 CMS
Blueprint Medicines Corporation $19.0005/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147449460 CMS
PFIZER INC. $21.9305/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131321864 CMS
Regeneron Healthcare Solutions, Inc. $98.2205/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114326537 CMS
PFIZER INC. $22.3705/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132042984 CMS
JAZZ PHARMACEUTICALS INC. $21.7805/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151297392 CMS
Novartis Pharmaceuticals Corporation $22.7705/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086997094 CMS
AstraZeneca Pharmaceuticals LP $23.9604/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104722405 CMS
AstraZeneca Pharmaceuticals LP $2.0704/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105847777 CMS
Novartis Pharmaceuticals Corporation $83.3304/18/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086997114 CMS
Myriad Genetic Laboratories, Inc. $7.7704/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152547916 CMS
ABBVIE INC. $425.0004/09/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1107465883 CMS
GENZYME CORPORATION $13.6804/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139942759 CMS
Stemline Therapeutics Inc. $25.1604/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142968293 CMS
SOBI, INC $27.8703/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141437265 CMS
AstraZeneca Pharmaceuticals LP $14.1003/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104371663 CMS
Eisai Inc. $14.7103/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110806638 CMS
Novartis Pharmaceuticals Corporation $83.3303/15/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086997112 CMS
Celgene Corporation $36.4103/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101189643 CMS
Alexion Pharmaceuticals, Inc. $24.7203/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093885483 CMS
E.R. Squibb & Sons, L.L.C. $13.2302/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101808881 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $6,141.32 32
PY2022 $46,162.52 90
PY2023 $17,335.67 81
PY2024 $11,836.09 113
PY2025 $15,743.22 129

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Recipient $2,489.12 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

13 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Regeneron Pharmaceuticals, Inc. $38.84 04/10/2024 Covered Recipient Non-Physician Practitioner A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1082398716
Recipient Regeneron Pharmaceuticals, Inc. $55.00 04/10/2024 Covered Recipient Non-Physician Practitioner A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1082398718
Recipient Regeneron Pharmaceuticals, Inc. $162.14 04/10/2024 Covered Recipient Non-Physician Practitioner A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1082398720
Recipient Regeneron Pharmaceuticals, Inc. $316.71 03/22/2024 Covered Recipient Non-Physician Practitioner A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1082398712
Recipient Regeneron Pharmaceuticals, Inc. $603.22 03/22/2024 Covered Recipient Non-Physician Practitioner A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1082398714
Recipient Regeneron Pharmaceuticals, Inc. $21.86 03/21/2024 Covered Recipient Non-Physician Practitioner A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1082398700
Recipient Regeneron Pharmaceuticals, Inc. $31.15 03/21/2024 Covered Recipient Non-Physician Practitioner A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1082398702
Recipient Regeneron Pharmaceuticals, Inc. $43.47 03/21/2024 Covered Recipient Non-Physician Practitioner A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1082398704
Recipient Regeneron Pharmaceuticals, Inc. $62.30 03/21/2024 Covered Recipient Non-Physician Practitioner A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1082398706
Recipient Regeneron Pharmaceuticals, Inc. $77.56 03/21/2024 Covered Recipient Non-Physician Practitioner A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1082398708
Recipient Regeneron Pharmaceuticals, Inc. $130.74 03/21/2024 Covered Recipient Non-Physician Practitioner A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1082398710
Recipient Regeneron Pharmaceuticals, Inc. $134.92 03/20/2024 Covered Recipient Non-Physician Practitioner A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1082398698
Recipient Regeneron Pharmaceuticals, Inc. $811.21 02/26/2024 Covered Recipient Non-Physician Practitioner A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1082398696